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ABSTRACT
Cholesterol-Lowering of Pantethine
is Due to the Hydrolysis
Product Cysteamine
by
Caran Graves, Master of Science
Utah State University, 1987
Major Professor:
Dr. Carol T. Windham
Department:
Nutrition and Food Sciences
Pantethine, a precursor of coenzyme A, has been
shown to reduce serum cholesterol levels in
hypercholesterolemic rabbits.

The enzyme pantetheinase

rapidly hydrolyzes pantethine to the vitamin
pantothenic acid and the amino thiol cysteamine.
This study was designed to compare the effect of
cysteamine and pantothenate supplementation with that
of pantethine on hypercholesterolemic rabbits.

New

Zealand white rabbits were fed a 0.5 % cholesterol diet
for 5 weeks;

treatment groups received only the high

cholesterol diet (control), or a high cholesterol diet
supplemented with 1% pantethine, or an equimolar amount
of pantothenic acid or cystamine (the disulfide of
cysteamine).

Blood samples were drawn weekly and total

serum cholesterol levels analyzed enzymatically.
Pantethine and cystamine both significantly reduced

vii

serum cholesterol levels (p
had no effect.

<

0.05); pantothenic acid

Separation of serum lipoproteins using

a preparative ultracentrifuge showed an increase in
very low density, intermediate density and low ctensity
lipoproteins.
A second experiment was conducted to compare the
effect of cystamine with other small thiols;

the

protocol was similar to the first experiment with
treatment groups consisting of a high cholesterol
control, cystamine, cystine or 2,hydroxyethyl
disulfide.

There was no significant reduction in serum

cholesterol levels between tre a tment groups, although
the cystamine supplemented group tended to be lower
than the other groups.
(76 pages)

INTRODUCTION
Cholesterol and Coronary Artery Disease
Coronary heart disease is the leading cause of
death in the United States.

Recent estimates indicate

that 5.4 million Americans have symptomatic coronary
heart disease (American Medical Association, 1985;
Levy, 1986).

While many factors have been associated

with heart disease, high serum cholesterol levels are
consistently identified with increased risk of
developing coronary heart disease (Wilhelmset et al.,
1973; Wright and Fredrickson, 1970; Keys,

1980).

Epidemiological studies show that the chance of
developing coronary heart disease rises as serum
cholesterol and low density lipoprotein (LDL) levels
rise. The 20 year report (Kagan et al., 1962) of the
Framingham Study noted that increasing serum
cholesterol levels correlated with an increased
incidence of coronary heart disease; participants with
total serum cholesterol levels over 260 mg/dl had the
greatest risk.

The Seven Countries Study (Keys, 1980),

involving over 10,000 men from Finland, Greece, Japan,
Yugoslavia, Italy, Netherlands, and the United States,
found that the incidence of coronary disease was
directly related to increased serum 9holesterol levels.
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A prospective study of 855 Swedish men also identified
high serum cholesterol levels (

<

270 mg/dl) as a

significant risk factor for coronary heart disease
(Wilhelmset et al., 1973).
Recent clinical trials demonstrate the benefits of
reducing serum cholesterol levels.

The Leiden

Intervention Trial (Arntzenius et al., 1985) reduced
serum cholesterol levels by 10% over a two year period
with dietary modifications.

Coronary lesion growth

(measured by coronary angiography) diminished
-

significantly during this period and correlated with
decreased serum cholesterol levels.
The Lipid Research Clinics Coronary Primary
Prevention Trials (1984a, 1984b) used the bile acid
sequestrant cholestyramine to study the effects of
reduced serum cholesterol levels on serum lipids.
Cholestyramine treatment was associated with an average
reduction in serum cholesterol and LDL cholesterol of
13.4 and 20.3%, respectively.

There was a 19% decrease

in the occurrence of coronary heart disease death or
non-fatal myocardial infarction associated with
cholestyramine use.
Current epidemiological and clinical data indicate
a strong correlation between high serum cholesterol
levels and coronary heart disease.

On the basis of

this evidence the National Institutes of Health
/

(Consensus Development Conference, 1985) and American

3

Heart Association (1984) recommend that the people of
the United States actively try to reduce their risk
factors for developing cardiovascular diseases,
including reduction of serum cholesterol and LDL
cholesterol levels.

Aggressive treatment is

recommended for those with serum cholesterol levels
above the 90th percentile of the population.

While

dietary modifications may suffice for the majority, the
use of therapeutics may be needed for high risk
individuals (Levy, 1980; American Heart Association,
1983; Hoeg et al., 1986).
The major pharmacological treatments of
hypercholesterolemia are bile-acid sequestrants and
nicotinic acid (Levy, 1980; DeGraph, 1984; Hodges &

Smith, 1984).

These drugs reportedly decrease

cholesterol levels 10% to 15% but have unpleasant side
effects (Levy, 1980).

Other therapeutic agents

available in the U.S. include probucol and clofibrate;
clofibrate lowers triglyceride levels but has limited
effect on serum cholesterol.

Pantethine, a derivative

of the vitamin pantothenic acid, is being studied in
Italy as a hypocholesterolemic agent (Maggi et al.,
1982; Angelico et al., 1983);

it is marketed as a

hypolipidemic agent, Pantosin (Daiichi Seiyaku Co,
Tokyo, Japan), in Japan.
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Pantethine and its Metabolites
Pantetheine, the sulfhydryl form of pantethine,
is composed of the vitamin pantothenic acid and the
disulfide of the aminothiol, cysteamine.

·Pantetheine

functions as the working arm of Coenzyme A and acyl
carrier protein; as such, pantetheine is widely
involved in the metabolism of carbohydrates, fat and
proteins; cholesterol synthesis directly involves
pantetheine (Abiko, 1975).

The sulfhydryl moiety of

cysteamine is the active site of the CoA molecule.
Pantethine and Serum Cholesterol
Human and animal studies show that pantethine
treatment lowers serum cholesterol levels.

Cattin and

colleagues (1985) compared pantethine treatment with
fenofibrate, a hypercholesterolemic drug, and found a
comparable hypocholesterolemic effect.

Hyperlipidemic

patients given pantethine showed a 12% reduction in
total serum cholesterol and a 33% decrease in serum
triglycerides, but no changes in HDL cholesterol levels
(Angelico et al., 1983).

Other researchers report

similar findings with hyperlipidemic diabetic patients
(Miccoli et al.,

1984) and dialysis patients (Donati

et al., 1986).
Recent reports indicate that pantethine alters
lipid profiles in cholesterol fed rabbits. Tomikawa and
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colleagues (1982) fed rabbits a diet containing 0.53
cholesterol supplemented with 13 pantethine; control
rabbits received a high cholesterol diet only.

Total

serum cholesterol and LDL cholesterol levels of
pantethine supplemented rabbits decreased significantly

(723 and 583 , respectively) after 4 weeks;

very low

density lipoprotein cholesterol was normalized, and
high density lipoprotein cholesterol increased.

These

results were confirmed by Carrara and colleagues (1984)
who also noted a decrease in the severity of
atherosclerotic lesion formation in the pantethine fed
rabbits.
Comparison of pantethine treatment with the
hypocholesterolemic drug, probucol, shows that both are
effective in lowering serum cholesterol levels (Tawara
et al., 1986).

The cholesterol-lowering effect was

even more pronounced when these compounds were used
simultaneously.
Oral administration of pantethine (70 to 1000
mg/kg/day) to cystinotic patients did not result in
detectable levels of serum pantethine up to five hours
after treatment (Wittwer et al., 1985).

Serum levels

of pantothenic acid and cysteamine did increase with
pantethine administration.

Blood samples from rats

taken 30 minutes after intravenous administrations of
pantethine showed over 50 percent present as free
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pantothenic acid (Ono et al., 1974).
The enzyme pantetheinase hydrolyzes pantethine to
pantothenic acid and cysteamine (Wittwer et al., 1983;
Abiko, 1975).

Pantetheinase activity has been

identified in horse and pig kidney, rat liver and human
serum (Abiko, 1975; Dupre and Cavallini, 1979; Wittwer
et al. 1983, Wittwer et al., 1985).

Rapid hydrolysis

of orally administered pantethine is indicated by the
lack of detectable serum pantethine in humans and rat
and the concomitant rise in pantethine's metabolites
(i.e. pantothenic acid and cysteamine).
Statement of the Problem
Pantethine reduces serum cholesterol levels in
cholesterol-fed rabbits.

The rapid hydrolysis of

pantethine by serum pantetheinase results in high
circulating levels of pantothenic acid and cysteamine
and no measurable pantethine.

It is possible that one

of the hydrolysis products, pantothenate or cysteamine,
produces the observed reduction in serum cholesterol
levels.

However, there have been no reports testing

pantethine's metabolites for their hypocholesterolemic
effect.
Objectives
The objective of this study is t6 examine the
effects of pantethine and its metabolites on serum
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cholesterol levels in cholesterol-fed rabbits.
Currently there are few drugs which effectively treat
hypercholesterolemia and those drugs which are
available have side effects which interfer with
compliance.

Pantehine and its metabolites have few

known side effects.

If one of pantethine's hydrolysis

products is an effective hypocholesterolemic agent, it
may prove useful in clinically reducing high serum
cholesterol levels.
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REVIEW OF THE LITERATURE
Coronary heart disease kills 550,000 Americans
annually, making it the leading cause of death in the
United States (Center for Disease Control, 1986).

An

estimated 5.4 million Americans have coronary heart
disease (Levy, 1986).

Depending upon the severity of

coronary heart disease, the direct medical costs and
indirect costs (loss of income) range from $4 to
approximately $9000 per person (Oster and Epstein,
1986).

Atherosclerosis is the leading cause of

myocardial and cerebral infarction which are the major
causes of death from coronary heart disease (Ross,
1986).

The lesions of atherosclerosis are

characterized by large lipid and cholesterol deposits;
the cholesterol is usually found as cholesterol esters
(Goldstein and Brown, 1977; Ross, 1986).

This

observation stimulates interest in the relationship of
cholesterol to atherosclerosis and coronary heart
disease.
Epidemiological Studies
The high cholesterol content of atherosclerotic
lesions is only one factor linking cholesterol with
with heart disease.

High serum cholesterol levels are

a major risk factor for developing coronary heart
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disease (Wilhemset et al., 1973).

Epidemiological

studies indicate an increase in the incidence of
coronary heart disease as serum cholesterol

ris~s.

The Framingham study, begun in 1949, prospectively
analyzed coronary heart disease and hypertension in a
group of 5,000 subjects.

Subjects received biennial

follow-up examinations which included a medical
history, physical and laboratory tests including serum
cholesterol levels.

An eight year report of the

Framingham Study (Kagan et al., 1962) noted that
increased serum cholesterol levels correlated with an
increased incidence of coronary heart disease; this
risk was most pronounced in younger participants (40 to
49 years at the beginning of the study) with total
serum cholesterol levels over 260 mg/dl.

High blood

pressure, smoking and obesity also correlated with
increased rates of cardiovascular disease.
The Seven Countries Study (Keys, 1980) involved
over 10,000 men from Finland, Greece, Japan,
Yugoslavia, Italy, Netherlands, and the United States.
These men were followed for 10 years to assess the
relationship of blood pressure, serum cholesterol,
smoking, activity level, weight, pulse rate, diet and
respiratory function with coronary heart disease; only
blood pressure and serum cholesterol were associated
with an increased incidence of coronary disease.

The

10
relationship between these variables and coronary heart
disease was direct.

Serum cholesterol levels

correlated significantly with the ten year death rate
from coronary heart disease (r

= 0.8) and accounted for

64% of variability among cohorts in death rate from
coronary heart disease.

This high correlation was also

identified with non-fatal coronary heart disease
(r = 0.79).

The Pooling Project (Pooling Project Research
Group, 1978) compiled and analyzed the results of five
prospective studies on coronary problems.

This

retrospective study involved men aged 40 - 64 years and
compared coronary heart disease rates at five quintiles
of serum cholesterol (from

< 194 mg/dl to > 268 mg/dl).

The mean serum cholesterol levels of individuals with
coronary disease was significantly higher than for
those who were asymptomatic.

The difference in means

was most extreme at younger ages (19.7 mg/dl for 40 to
44 years) and least for older groups (9.8 mg/dl for 50
to 55 years).

This relationship appears curvilinear

with the risk of coronary heart disease rising
dramatically in the upper quintiles.

However, a recent

study involving over 350,000 men found that the
relationship between serum cholesterol and coronary
heart disease is not curvilinear but linear (Stamler et
al., 1986).
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Intervention Trials
Prospective studies identified high serum
cholesterol levels as related to the development of
coronary artery disease.

Intervention studies attempt

to assess the effect of varying treatments, including
decreasing serum cholesterol levels, on individuals
with symptomatic coronary heart disease.

Recent

clinical trials demonstrate the benefits of reducing
serum cholesterol levels.
The National Heart, Lung and Blood Institute
a nalyzed the effect of diet and/or drug therapy on
coronary arteriosclerosis in patients with
hypercholesterolemia (Brensike et al., 1984).

In this

double-blind study, diet alone reduced serum
cholesterol levels 11 3 ; use of cholestyramine with the
diet dropped serum cholesterol levels a total of 31 3 .
Coronary angiography of arterial lesion growth
(measured by changes in lumen diameter) following five
years of treatment showed that the diet group had 493
progression of coronary artery disease versus only 353
(p

<

0.05) in those receiving both dietary and

pharmacologic treatment.

Cholestyramine decreased

serum cholesterol levels and slowed the progression of
coronary heart disease.
The Lipid Research Clinics

Corona~y

Primary

Prevention Trials (1984a, 1984b) analyzed the long term
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benefits of drug therapy on serum lipids using the bile
acid sequestrant cholestyramine.

The clinics followed

3,810 hypercholesterolemic men from the United States
who were at high risk for coronary heart disease
based upon serum lipid levels above the 95th percentile
(265 mg/dl).

All participants followed a cholesterol-

lowering diet and were assigned to either a
cholestyramine or placebo treatment group.

After ten

years the cholestyramine group averaged cholesterol
reductions of 13.4%; diet alone reduced serum
cholesterol levels 8.5%.

While there was no difference

in total deaths between treatment groups, coronary
heart disease death or non-fatal myocardial infarction
decreased 19% with cholestyramine use.
The Leiden Intervention Trial (Arntzenius et al.,
1985) analyzed the effect of a cholesterol-lowering
diet on coronary lesion growth in 39 men with stable
angina pectoris.

Dietary modifications resulted in a

10% decrease in cholesterol levels over a two year
period.

Lesion growth was assessed by angiography pre-

and post-treatment.

Coronary lesion growth diminished

significantly during this period and correlated with
decreased serum cholesterol levels.
Along with the correlation of serum cholesterol to
coronary heart disease development in humans, animal
studies indicate that increasing cholesterol levels
coincide with the development of arterial lesions.
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Rabbits and nonhuman primates show evidence of lipid
accumulation in the arterial lumen begining at seven to
ten days (Poole and Florey, 1958; Silkworth et al.,
1975; Faggiotto et al., 1984a; 1984b).

The

accumulation of lipid results in the formation of
atherosclerotic plaques within 12 months of beginning
the diet (Faggiotto et al., 1984b).
Although high serum cholesterol levels have not
been proven to cause coronary heart disease, the
correlation is strong.

On the basis of current

epidemiological and clinical data, the American Medical
Association, National Institutes of Health and the American Heart
Association (Consensus Conference, 1985; National
Institutes of Health, 1985; American Heart Association,
1984) recommend that the people of the United States
actively try to reduce their risk factors for
developing cardiovascular diseases.

The

recommendations include maintaining a desirable body
weight and reducing serum cholesterol levels.
While dietary modifications may suffice for the
majority, the use of therapeutics may be needed for
high risk individuals
1986).

(Levy, 1980; Hoeg et al.,

Aggressive treatment is recommended for those

individuals with serum cholesterol levels above the
90th percentile of the population; for men 35 years and
older, 270 mg/dl represents the 95th percentile
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(Rifkind and Segal, 1983).
Bile acid sequestrants and nicotinic acid provide
the major form of drug therapy for hypercholesterolemic
patients (Levy, 1980; Hunninghake, 1983; DeGraph,
1984).

These drugs have unpleasant side effects that

may limit patient compliance.

Probucol also lowers

serum cholesterol levels, mainly through the reduction
of LDL cholesterol levels (Levy, 1980; DeGraph, 1984).
However, it is also associated with a decrease in HDL
cholesterol levels.
Pantethine and its Metabolites
Pante thine
The sulfhydryl of pantethine, pantetheine, is
composed of the vitamin pantothenic acid and an
aminothiol, cysteamine (see Figure 1).

As part of

Coenzyme A (CoA), the sulfhydryl moiety cysteamine is
the active site of the molecule (Majerus et al., 1965;
Pugh and Salih, 1965; Abiko, 1975).

Because pantetheine

can be synthesized in vitro from pantothenic acid and
cysteine, it has not been identified as an essential
nutrient.

As the working arm of Coenzyme A and acyl

carrier protein, pantetheine functions widely in the
metabolism of carbohydrates, fat and proteins.
Cholesterol synthesis directly involves pantetheine
(Abiko, 1975; Sabine, 1977; Stryer, 1981).

Synthesis
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of cholesterol begins with two units of acetyl CoA, and
CoA involvement continues through the first three steps
of cholesterol synthesis to the formation of
mevalonate from hydroxymethylglutaryl CoA (Sabine,
1977; Stryer, 1981).
Pantothenic acid
In 1933 Williams et al.

(1933) first described and

identified an essential growth factor for yeast which
they named pantothenic acid (from the Greek meaning
"everywhere").

The active agent in the chick anti-

dermatitis factor studied by Woolley and co-workers
(1938,

1939) was also identified as pantothenic acid

(Jukes, 1939).

The discovery by Lipmann (1945) of a

coenzyme of acetylation (CoA) and identification of
pantothenate's biochemical role as part of CoA (Lipmann
et al., 1947) provided a biochemical basis for
pantothenic acid's biological function.

Pantothenate

exists in tissue in a bound form (e.g. as CoA
pantethine,Acyl Carrier protein); very little is
present in a free form (Novelli, 1953; Abiko, 1975).
Blood and serum contain high levels of pantothenic acid
(Wyse et al., 1985).

Pantothenic acid in serum is

present only in an unbound form, while pantothenate in
erythrocytes mainly occurs in bound forms.
While pantothenic acid is an essential nutrient,
its ubiquitous distribution precludes widespread,
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naturally occurring deficiencies.

Deficiency has been

experimentally induced in animals using pantothenatedef icient diets (Unna, 1940; Schaefer et al., 1942).
Pantothenic acid deficiency in humans can be caused by
providing a deficient diet or a pantothenate antagonist
(Bean and Hodges, 1954; Lubin et al., 1956; Hodges et
al.,

1957; 1959).

Deficiency symptoms include

decreased resistance to infection, malaise, changes in
sensation such as paresthesia, irritability,
alterations in insulin sensitivity and lesions of the
skin, nervous system and adrenal glands (Novelli, 1953;
Fox, 1984).

Most of these symptoms are non-specific

and are assumed to result from a wide-spread deficiency
of CoA and other active forms of pantothenic acid that
thus affect a variety of organ systems (Novelli, 1953;
Abiko, 1975).
Cysteamine
Cysteamine, the sulfhydryl moiety of pantethine,
has no known nutritional significance.

Cysteamine is

effective in treating acetaminophen overdose (Hamlyn et
al., 1981). Cysteamine and its disulfide, cystamine,
also afford short term protection against ionizing
radiation such as x-rays (Bacq et al.,
Alexander, 1964).

1953; Bacq and

This protective effect occurs only

when administered prior to exposure.

Eldjarn and
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Nygaard (1954) found that the period of effectiveness
corresponds to peak serum cysteamine/cystamine
concentrations following administration.

Serum

cysteamine concentration rises rapidly following oral
administration and returns almost to normal after 2
hours (Eldjarn and Nygaard, 1954).

The radioprotective

action of thiols appears to be the result of rapid
formation of mixed disulfides with proteins (Eldjarn
and Pihl, 1956).
Cysteamine (300 mg/kg) is used experimentally to
induce duodenal ulcers in rats (Selye and Szabo, 1973;
Man et al., 1984); a dose of 1 gm/kg in rats results in
a 70% mortality rate within 48 hours (Selye and Szabo,
1973).

While the exact mechanism of ulcer formation is

unknown, cystearnine administration is known to increase
gastric acid output, pepsin activity, serum gastrin and
to decrease gastric emptying time while altering the
duodenal mucosa (Man et al., 1984).
Cysteamine is used clinically to treat cystinosis.
Cystinosis is a rare inherited disease characterized by
cellular accumulation of free cystine (Schneider and
Schulman, 1983; Rosenberg and Scriver, 1974).
Deposition of cystine crystals in the eyes, bone
marrow, leukocytes and soft tissues results in growth
retardation, vitamin D-resistant rickets, anemia,
photophobia and renal failure; prior to dialysis, most
children with cystinosis died of renal failure.
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Cysteamine/cystamine depletes cystinotic cells, both in
vivo and in vitro, of free cystine (Thoene et al.,
1976; Yudkoff et al., 1981;

Da Silva et al., 1985).

Disulfide interchange of cysteine-cysteamine has been
proposed as a depletion mechanism (Gahl ahd Bercu,
1985; Gahl et al., 1985b).
Rashes, lethargy, hyperthermia and hepatotoxicity
are reported side effects of cysteamine treatment in
cystinosis ( Corden et al. , 1981 ; Avner et al. , 1983).
The report of hepatotoxicity is limited to a single
case and may not be due to cysteamine treatment but
rather to hepatic veno-occulusive disease that occurs
with long-standing cystinosis (Gahl et al., 1983).

The

other adverse reactions occurred only with initial
administration of high doses of cysteamine, and in all
patients cysteamine was successfully readministered
(Corden et al., 1981).

Despite concerns about the

possible side effects of cysteamine there have been few
reports of adverse side effects at doses of 3 - 90
mg/kg (Yudkoff et al., 1981; Da Silva et al., 1985;
Schneider, 1985).
Pantethine and Cholesterol
Pantethine has been reported to alter lipid
profiles in cholesterol fed humans and rabbits.

The

cholesterol-lowering effects of pantethine have been
demonstrated in hyperlipidemic patients.

Maggi and
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colleagues (1982) studied the effect of pantethine
treatment on hyperlipidemic patients who had showed
limited response to low fat, low cholesterol diets.
These patients complied with their diets and received
900 mg of pantethine daily; there was no control group.
Treatment was associated with a 203 decrease in total
serum cholesterol levels after 90 days (p

0.01).

Angelico and partners (1983) fed hyperlipidemic
patients on a low fat diet for two weeks (baseline),
and then provided either 1200 mg pantethine or a
placebo to each patient (patients continued on the
diet).

The cross-over design included two 30-day test

periods (placebo and pantethine).

Pantethine treatment

resulted in a 123 reduction in total serum cholesterol
(p

< 0.01

versus baseline levels, and a 333 decrease in

serum triglycerides, but no changes in HDL cholesterol
levels.
Cattin and colleagues (1985) compared pantethine
treatment with fenofibrate, a clofibrate analogue.

Two

groups of hypercholesterolemic patients received either
fenofibrate or pantethine (900 mg/day) for 4 months;
all patients consumed low fat diets.

Both pantethine

and fenofibrate resulted in a significant (p

<

0.001)

decrease in serum cholesterol levels after eight and 16
weeks of treatment.

Serum cholesterol levels decreased

16 percent after 16 weeks of pantethine treatment
versus 203 with fenofibrate.

LDL cholesterol also
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decreased significantly while HDL cholesterol remained
unchanged.
Both diabetes and kidney failure are associated
with increased cholesterol levels.

Pantethine

treatment decreases serum cholesterol levels in
hyperlipidemic diabetic patients (Miccoli et al.,
1984) and dialysis patients (Donati et al., 1986)
treated with pantethine.

In none of these studies

were any adverse effects of pantethine treatment noted.
Studies with rabbits also indicate that pantethine
lowers serum cholesterol levels.

Tomikawa and co-

workers (1982) fed three groups of rabbits diets of
a) standard diet b) high cholesterol diet with 5%
cholesterol) or c) the high cholesterol diet with 1%
pantethine. Fasting blood samples were analyzed for
lipid content using a density gradient.

Total serum

cholesterol and low density lipoprotein (LDL)
cholesterol levels of pantethine supplemented rabbits
began to decrease significantly after 10 days on the
test diet.

Cholesterol and LDL cholesterol levels

reached their lowest levels (74% and 79%, respectively)
after 14 days; these levels were maintained throughout
the remaining 14 days of treatment.

However,

cholesterol levels in pantethine treated rabbits
remained about four times those of control rabbits
(103.5 mg/dl for the pantethine treated group vs 27.6

22
mg/dl for the high cholesterol group at day 14).

Very

low density lipoprotein cholesterol decreased
significantly (p

< 0.01) and high density lipoprotein

cholesterol increased (p

<

0.05).

Carrara and colleagues (1984) confirmed these
results and also noted a decrease in the severity of
atherosclerotic lesion formation in the pantethine fed
rabbits.

New Zealand rabbits were placed into

treatment groups similar to those used by Tomikawa;
fasting blood samples were analyzed for cholesterol
using enzymatic methods.

In addition, samples of

aortic tissue were studied for atherosclerotic lesion
formation.

While pantethine was found to lower serum

cholesterol levels significantly (p < 0.01) when
compared with cholesterol only rabbits, this decrease
was not significant until after 65 days of treatment
and was about 50% of cholesterol only rabbits.

After

90 days of treatment, pantethine resulted in a 65%
decrease in total cholesterol levels (370 mg/dl vs 1050
mg/dl).

Visual analysis of aortic and coronary artery

tissue indicated a lowering of lesion formation in
pantethine fed rabbits, but total cholesterol content
of these tissues did not differ from those of the
cholesterol only group.
A recent studied analyzed the dose-response effect
of pantethine, compared pantethine treatment with the
hypocholesterolemic drug probucol, and studied the
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effect of combined treatment of probucol and
pantethine on the serum cholesterol levels of
hypercholesterolemic rabbits (Tawara et al., 1986).
Pantethine was as effective as probucol in reducing
serum cholesterol levels; probucol was associated with
a decrease in HDL cholesterol levels while pantethine
was not.

Pantethine exhibited a dose-response

relationship with serum cholesterol levels with
reductions of 25%, 32% and 70% (0.25 %, 0.5 % and 0.75%
pantethine supplementation, respectively) at nine
weeks.

Combined pantethine and probucol treatment

resulted in lower cholesterol levels than either drug
achieved separately and resulted in higher HDL levels
than did probucol treatment alone.
Studies on fibroblasts show a reduction in
cholesterol synthesis with pantethine.

Ranganathan and

colleagues (1982) incubated human skin fibroblasts with
pantethine; incorporation of radiolabled acetate or
mevalonolactone into sterols was measured.

Pantethine

incubation resulted in a 50% to 80% decrease in
cholesterol synthesis (as measured by uptake of
radiolabled precursors) and a simultaneous increase in
intermediate methyl sterols; the magnitude of
pantethine's effect was dose related.

Other sulfur-

containing compounds (dithiothreitol, glutathione, CoA,
and cystine) did not reduce cholesterol synthesis.
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The mechanism of pantethine's hypercholesterolemic
action is unknown.

Because of pantethine's role in

Coenzyme A and acyl carrier protein, changes affecting
lipid metabolism and cholesterol levels may occur
through alterations involving these compounds.
However, pantetheine is hydrolyzed to pantothenic
acid and cysteamine by a specific enzyme,
pantetheinase, (Wittwer et al, 1983; Abiko, 1975) and
may not remain intact long enough to result in a
therapeutic effect.
Pantetheinase is specific for pantetheine and is
inhibited by high concentrations of pantothenate
(Abiko, 1975; Wittwer et al., 1983).

Pantetheinase has

been purified from horse kidney (Dupre and Cavallini,
1979), rat liver and kidney (Abiko, 1975), and pig
kidney (Wittwer et al., 1983).

Pantetheine-hydrolyzing

activity was noted in rat and human intestinal tissue
(Wittwer et al., 1985).

The level of pantetheinase

activity in intestinal tissue appears to be sufficient
to ensure nearly complete hydrolysis of pantethine
during absorption (Shibata et al., 1983; Wittwer et
al., 1983).
Evidence of plasma pantetheine-hydrolyzing activity
exists in rats and humans (Ono et al., 1974; Wittwer et
al., 1985).

Blood samples from rats taken 30 minutes

after intravenous administrations of pantethine showed
over 50% present as free pantothenic acid, indicating
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rapid hydrolysis of the injected dose.
patients fed pantethine (70 -

In cystinotic

1000 mg/kg/day), no serum

pantethine was detected at any time after
administration.

However, serum levels of pantothenic

acid and cysteamine increased dramatically (Wittwer et
al., 1985).

The authors also noted a 14% drop in serum

cholesterol levels after two weeks of pantethine
treatment.
The rapid hydrolysis of pantethine by pantetheinase
leads to speculation that one of the hydrolysis
products, rather than pantethine itself, may be the
active hypercholesterolemic compound.
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METHODOLOGY
Pantethine reduces serum cholesterol levels in both
cholesterol-fed animals and hypercholesterolemic
humans.

Pantethine is rapidly hydrolyzed to its

component metabolites, pantothenic acid and cysteamine,
by the enzyme pantetheinase.

It is hypothesized that

one of these metabolites rather than pantethine
produces the reported hypocholesterolemic effect.

This

study is designed to compare the effect of pantethine
with the effects of pantothenic acid and cysteamine on
serum cholesterol levels in hypercholesterolemic
rabbits.

To provide easy comparison, the experimental

design is similar to that used by Tomikawa and
colleagues (1982) in researching the effect of
pantethine in experimentally hypercholesterolemic
rabbits.
Experiment 1:

Comparison of Pantethine, Cystamine

and Pantothenic Acid on Serum Cholesterol in
Cholesterol-Fed Rabbits
Fourteen male New Zealand white rabbits weighing
2.0 to 2.5 kg (4 to 6 weeks) were ordered from local
suppliers.

The number of rabbits in the study was

limited by the space available at the Utah State
University Lab Animal Research Center.
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All rabbits were fed a high cholesterol diet.

The

cholesterol only group served as a control for
cholesterol levels; the pantethine group served as
reference group to compare the effect of pantothenic
acid and cystamine.

The rabbits were placed in one of

four treatment groups:

cholesterol, pantethine,

pantothenic acid, and cystamine (the disulfide of
cysteamine).

The rabbits were divided into treatment

groups by taking the four rabbits with the highest pretreatment serum cholesterol levels (individual serum
cholesterol level reported in Appendix 1) and randomly
assigning them to one of the four treatment groups.
This procedure was repeated with the rabbits having the
four lowest serum cholesterol levels; the remaining
rabbits were then randomly assigned to treatment
groups.
Diets were custom made by ICN Nutritional
Biochemicals (Cleveland, OH) and consisted of Purina
Rabbit Chow with 0.5 % cholesterol (supplied by ICN
Biochemicals), 1% by weight pantethine or an equimolar
amount of cystamine, or pantothenic acid (all purchased
from Sigma Chemical Co., St. Louis, MO.).

The rabbits

were fed 150 g of food daily and residual food (if any)
was weighed; water was supplied ad lib.

Rabbits were

housed and cared for in the Lab Animal Research Center.
Fasting blood samples were drawn weekly for
analysis of total serum cholesterol levels.

Serum
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cholesterol levels were measured by the colorimetric
method of Allain and co-workers (1974).

This enzymatic

procedure couples the hydrolysis and oxidation of
cholesterol esters with a chromogenic system to produce
a dye with a maximum absorbance at 500 nm.

This

determination employs the following reactions:

1)

Cholesterol Esters

Cholesterol
esterase

Cholesterol + Fatty Acids
2)

Cholesterol +

o2

Cholesterol
Oxidase

Cholest-4-en-3-one + H o
2 2
3)

+

4-Aminoantipyrine +

p-Hydroxybenzene-sulfonate
Peroxidase

Quinoneimine Dye + 4H

2

o

All reagents and standards were purchased as a kit
from Sigma Chemical Co. (Cleveland, OH).
cholesterol assay is outlined in Table 1.

The
Absorbance

was measured using a Gilford 240 spectrophotometer.
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Table 1:

Procedures for total serum cholesterol
assay.

Reagent

Blank

dH 0
2

10 ul

standard

Control

Test Sample

10 ul

sample

10 ul

Cholesterol
Reagent
1. 0 ml

1. 0 ml

1.0 ml

Mix and incubate at 37°c for 10 minutes.
Read A

500

using the blank as a reference.

Total serum cholesterol was calculated using the
following formula:

Total cholesterol (mg/dl)

A

test

A

standard

500

=

500

In this study, the relationship

X [standard]

between the absorbance

at 500 nm and total serum cholesterol showed a linear
relationship up to a concentration of 800 mg/dl.
Serum lipoprotein separation was performed prior to
treatment and after 5 weeks.

The separation was

carried out using the density gradient method of Hinton
et al.

(1974); this method does not separate high

density lipoproteins.
Chylomicrons were removed after centrifuging at
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15,000 r.p.m. for 180 minutes (Nelson, 1972) using a
Beckman model J-21C preparative centrifuge and a JA-20
rotor (Beckman Instrument Co., Palo Alto, CA).
Serum samples were adjusted to a density of 1.22 by
adding 0.32 g/ml of solid NaBr.
were prepared as follows:

A)

Three stock solutions
11.4 g NaCl+ 0.1 g

EDTA/L, d

=

1.003; B) 263 g NaBr + 11.4 g NaCl+ 0.1 g

EDTA/L, d

=

1.205; C) 582 g NaBr/L, d

=

1.424.

All

chemicals were purchased from Aldrich Chemical Co.
(Milwaukee, WI.).

To form the density gradient, 0.7 ml

of solution C was placed in a 12.6 ml nitrocellulose
ultracentrifuge tube (Beckman Instrument Co.) and 0.7
ml of density adjusted plasma was layered on top.
Linear density gradients were formed using 5.6 ml each
of solutions A and B.
The density gradients were centrifuged at 30,000
r.p.m. for 2 hours in a Beckman model L3-50 preparative
ultracentrifuge using a SW-41 swinging bucket rotor.
The density gradients were analyzed using a Beckman
Fraction Recovery System and Isco absorbance monitor
model UA-4 (Isco Instrument Specialties Co., Lincoln,
NE.) at A240 •

There was no quantitative analysis

performed on the separated fractions.
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Experiment 2:

Comparison of Pantethine, Cystamine,

Cysteamine, and 2-Hydroxyethyl Disulfide
on Serum Cholesterol in
Cholesterol-Fed Rabbits
A second experiment was performed to compare the
effects of other low-molecular weight thiols on serum
cholesterol levels in hypercholesterolemic rabbits.
The disulfide forms of the following thiols were used:
cysteamine (cystamine), cysteine (cystine), 2mercaptoethanol (2-hydroxyethyl disulfide); all
chemicals were purchased from Aldrich Chemical Co.
(Milwaukee, WI) and are shown in Figure 2.

HO'-.
SH
CYSTEAMINE

NH3

/'....

'V

'-sH

2-MERCAPTOETHANOL

CYSTEINE

Figure 2:

Structures of cysteamine, cysteine,
and 2-mercaptoethanol.

The experimental design was similar to that used in
the first experiment.

Sixteen male New Zealand White

rabbits weighing 1.8 to 2.0 kg (4 to 6 weeks) were
obtained from R & R Rabbitry (Stanwood, WA).

The
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rabbits included four sets of littermates.

The rabbits

were divided into groups so that there was one member
of each litter per group. Baseline cholesterol levels
were obtained on each rabbit.
Four treatment groups, with four rabbits per group,
were established as follows:

cholesterol, cystamine,

cystine, 2-hydroxyethyl disulfide.

Treatment groups

were fed a 0.5% cholesterol diet supplemented
with molar equivalents of one of the test compounds at
levels equal to 1% pantethine.

Total serum cholesterol

levels were analyzed using the assay previously
described;

serum cholesterol concentrations were

calculated from a standard curve run with the serum
samples.

Lipoprotein separation was not performed.
Analysis of Data

Weekly, individual cholesterol levels were averaged
within treatment groups.

Analysis of variance to test

for significance among mean treatment cholesterol
levels was conducted weekly using Minitab Statistical
Package (Pennsylvania State University, University
Park, PA) according to the following model:
Y .. =
lJ

T.
l

+

e ..
lJ

where Y .. is cholesterol level for each observation, T.
lJ

it the variation associated with each treatment, and

l
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e .. is variation due to individu a l differences.
lJ
For any week in which significant differences among
means were found, treatment means were analyzed for
least significant differences using the Fisher Least
Significant Difference test (Ott, 1977) to determine
which specific treatments affected serum cholesterol
levels.
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RESULTS
The purpose of this study was to compare the effect
of pantethine and its metabolites, pantothenic acid and
cysteamine, on serum cholesterol levels in
hypercholesterolemic rabbits.

The results of a second

experiment comparing the effects of small thiols on
serum cholesterol levels are also reported.
Experiment 1:

Comparison of Pantethine, Cystamine

and Pantothenic Acid on Serum Cholesterol in
Cholesterol-Fed Rabbits
All experimental diets were well tolerated, with
each group consuming an average of 150 gm/day; this
provided 750 mg cholesterol per day and 1500 mg
pantethine, 600 mg cystamine or 1300 mg pantothenic
acid daily.
period.

All rabbits gained weight during the test

Analysis of variance on the serum cholesterol

levels of treatment means showed a significant
difference (p

<

0.005) after three weeks of

supplementation (Figure 3).

Treatment means were

analyzed for least significant differences.

This

analysis indicated that cystamine and pantethine
supplemented groups were significantly different from
the cholesterol only and pantothenic acid groups (p
0.05).

<

Serum cholesterol levels in the pantethine and

3 .5

1200

•

Ocholeaterol
0 Pantethine
• Cyataaine
• Pantothenate

1
Figure 3:

2

3

4

5

TIME (weeks)
Total serum cholesterol response of
cholesterol-fed rabbits to pantethine
and its metabolites.
(*, p < 0.05; **, p < 0.005).
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cystamine fed rabbits were reduced an average of 21 %
and 30%, respectively when compared to the cholesterol
only group (Table 2).

Table 2:

Total serum cholesterol levels (mg/dl)
by treatment group--Experiment 1
(mean+ standard deviation).

Week

Group
Cholesterol
SD

Pantethine
SD

Pantothenate
SD

70
383
728
815
1017
1121

75
249
555
582
778
864

71
292
694
782
1144
1264

x

0

1
2
3
4
5

18
83
74
11
76
81

x

18
98
125
79
186
205

Cyst amine
SD

x

x

14
78
122
75
91
120

63
300
571
630
800
806

16
157
140
62
198
235

Serum lipoprotein separation indicated a marked
increase in the the level of very low density,
intermediate density and low density lipoproteins with
cholesterol feeding;

the increase in intermediate

density lipoproteins was most pronounced.

An example

of the changes seen in serum lipoprotein fractions preand post treatment is presented in Figure 4.

There

appeared to be no noticeable difference in lipoprotein
profiles associated with any treatment.
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Pre- (......... 1 and post-treatment ( - ) serum
lipoprotein profiles of cholesterol treated
rabbits.

Experiment 2:

Comparison of Cystamine, Cystine,

and 2-Hydroxyethyl Disulfide on
Serum Cholesterol
The significant reduction in serum cholesterol
levels with cystamine supplementation led to
speculation regarding the specificity of this thiol in
reducing serum cholesterol levels.

A second experiment

was conducted comparing cystamine with the disulfides
of two structurally similar, low-molecular weight
thiols, cystine and 2-hydroxyethyl disulfide.
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The 2-hydroxyethyl disulfide diet was not as wellaccepted as the other diets.

In order to avoid any

differences in serum cholesterol levels due to food
intake, all groups were fed to match the intake of the
2-hydroxyethyl group.

The average intake was 110

gm/day, resulting in a total of 550 mg cholesterol
daily and either 450 mg cystamine, 480 mg cystine or
300 mg of 2-hydroxyethyl disulfide.

This intake level

resulted in a 27% decrease in cholesterol and
supplement intake compared with that of experiment 1.
There were no adverse effects noted from any of the
diets.
None of the test compounds significantly reduced
serum cholesterol levels, nor did cystamine treatment
significantly reduce cholesterol levels.

There was

considerable variation within the groups that may have
made achieving significance difficult (Table 3,
Appendix 2).
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Table 3:

Total serum cholesterol levels (mg/dl) by
treatment group--Experiment 2 (mean +
standard deviation).

Week

Group
Cholesterol
SD
x

0
1
2
3
4
5
6
7

60
254
545
773
660
1155
1393
1276

12
186
290
286
264
305
326
222

Cyst amine
SD
x
60
249
410
563
610
964
1078
1118

8
290
60
45
223
186
141
179

Cystine

x

60
221
496
742
750
1258
1304
1294

SD
4
141
280
326
254
392
344
367

2,Hydroxyethyl
SD
x
78
308
538
655
670
1053
1239
1548

49
183
284
172
172
231
197
211

The serum cholesterol levels of the control group
were similar to those of experiment 1 after five weeks
of treatment; however, at week five,

the cystamine

group had serum cholesterol levels 20% higher than in
experiment 1.

Despite the lack of significant

reductions, cholesterol levels in the cystamine treated
group tended to be lower than for the other groups
(Figure 5).

There was no significant difference in

serum cholesterol levels among the litters (Figure 6).
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Figure 5:

Total serum cholesterol response of
cholesterol-fed rabbits to cystamine, cystine,
and 2-hydroxyethyl disulfide.
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DISCUSSION
Many researchers have identified pantethine as an
effective hypocholesterolemic agent; however, there
have been studies reported in which pantethine did not
significantly reduce serum cholesterol levels.

A study

comparing pantethine to tiadenol (a hypocholesterolemic
drug)

treatment found that pantethine treatment did

not reduce total serum cholesterol nor LDL cholesterol
levels in 30 hypercholesterolemic patients (Da Col et
al.,

1984).
Rubba and colleagues compared the effectiveness of

short-term (1 month) treatment of pantethine versus
fenofibrate (1985).

They found that while fenofibrate

treatment resulted in significant reductions in serum
cholesterol levels, pantethine treatment lowered serum
cholesterol levels a non-significant 43 .
Other researchers have noted significant decreases
with pantethine treatment of some serum lipid
fractions, namely triglycerides and VLDL cholesterol,
but not in total serum cholesterol (Maggi et al.,
1982).
The cholesterol-lowering effect of pantethine in
cholesterol-fed rabbits was confirmed in this study,
although the reductions were considerably less than
those reported by Tomikawa et al. (1982).

However, in
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experiment 1, cystamine, a metabolite of pantethine,
provided a reduction of serum cholesterol levels
similar to that of pantethine.
lower serum cholesterol levels.

Pantothenate did not
The second experiment

was inconclusive regarding the specificity of
cysteamine's action.
In experiment 2, cysteamine did not have the same
hypocholesterolemic response as in experiment 1.

This

may be due to different chemical sources (Sigma vs.
Aldrich) or to the wide variation within treatment
groups.

It is also possible that the decreased food

intake in experiment 2, and the concomitant decrease in
cystamine intake, may have lowered the given dose to a
non-therapeutic level.

Figure 7 compares the average

serum cholesterol levels of rabbits fed 750 mg
cholesterol/day (experiment 1) versus 550 mg
cholesterol/day (experiment 2) averaged across the
cholesterol only and cystamine groups during the first
5 weeks of treatment.

These two treatments occurred in

both experiments and provide an indication of the
response of serum cholesterol levels to changes in the
amount of cholesterol consumed (750 mg vs. 550 mg).
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Figure 7:

Weekly total serum cholesterol levels of
rabbits fed 750 mg cholesterol/day
(Experiment 1) or 550 mg cholesterol / day
(Experiment 2).

The response to any drug is dependent upon dose.
It the level is too low, there is no response; if it is
too high, there is an unwanted or toxic response
(Roberts, 1982; Gibaldi, 1984).

The effective dose is

based upon many interrelated variables of
pharmacodynamics and pharmacokinetics (Gibaldi, 1984).
Some hypocholesterolemic drugs, such as cholestyramine,
show a graded response beginnning at even low doses
(DeGraph, 1984).

However, nicotinic acid only begins
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to effectively reduce cholesterol levels at 50 - 500
times the recommended vitamin requirements (Hodges and
Smith, 19 84) •
Pantethine treatment has shown a dose-response
relationship in some studies.

Tawara and colleagues

(1986) compared the effect of varying doses of
pantethine on serum cholesterol levels and found that
the response was dose related.

A dose of 0.25%

pantethine resulted in a 25 % decrease in serum
cholesterol levels versus a 32% decrease at a dose of
0.5 %.

Ranganathan et al. (1982) found a similar

relationship for pantethine on cholesterol synthesis of
human skin fibroblasts.
The hypocholesterolemic effect of pantethine has
been attributed to alterations in CoA levels.

CoA

shunts acetate molecules into either the tricarboxylic
acid cycle (TCA cycle) for oxidation or into lipid and
sterol synthesis (Maggi et al., 1982; Gaddi et al.,
1984).

If increased CoA preferentially shifted acetate

into the TCA cycle and away from lipid and cholesterol
synthesis, then cholesterol levels would be lowered.
CoA can be synthesized from pantothenic acid; or
pantetheine, through direct phosphorylation, can bypass
the first three steps in CoA biosynthesis and rapidly
increase CoA levels in vitro (Shimizu and Abiko, 1965;
Abiko, 1975).

In view of the presence of pantetheinase
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activity in serum, pantethine may not enter the CoA
biosynthetic pathway intact; it may be hydrolyzed to
pantothenic acid prior to CoA biosynthesis.

However,

in this study pantothenic acid had no effect on serum
cholesterol levels, indicating some mechanism other
than increased levels of CoA may be responsible for the
hypocholesterolemic effect of pantethine.
The mechanism of pantethine's effect on serum
cholesterol is unknown.

Shinomiya and co-workers

(1980) found that cholesterol esterase activity
increased in rat arterial walls on a high cholesterol,
pantethine supplemented diet when compared with an
unsupplemented diet.

Cholesterol esterase hydrolyzes

cholesterol esters, the cellular storage form of
cholesterol, following binding to lipoprotein receptors
and uptake by cells.

Increasing cholesterol esterase

activity helps remove circulating cholesterol and
decrease serum cholesterol levels.
Pantethine inhibits cholesterol synthesis in vitro.
Incorporation of radiolabled acetate into cholesterol
markedly decreases in human skin fibroblasts incubated
with pantethine (Ranganathan et al., 1982).

The

inhibition occurs in the conversion of lanosterol to
cholesterol; there are several intermediate steps in
this conversion and the exact point of inhibition is
unknown.

The effect of other sulfur-containing

compounds (dithiothreitol, glutathione, and cystine)
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were compared with pantethine and had no effect on
cholesterol biosynthesis; cystamine was not tested.
The hypocholesterolemic effect of pantethine and
cysteamine may result from the effect of
thiol:disulfide exchanges on enzyme systems.

Ziegler

(1985) states that thiol:disulfide exchange may alter
enzyme activity and serve to regulate enzyme activity.
One enzyme system in which this mechanism appears to
work is 3-hydroxy-3-methylglutaryl-CoA (HMGCoA)
reductase. HMGCoA catalyzes the first committed step in
the biosynthesis of cholesterol by reducing HMGCoA to
mevalonate.

Gilbert and Stewart (1981) found that

thiols such as HMGCoA and CoA rapidly inactivate HMGCoA
reductase.

Activity can be restored with

dithiothreitol.

Dithiothreitol inhibits disulfide

formation, so these researchers speculate that
disulfide formation may be responsible for inactivation
of HMGCoA reductase.

The effect of cystamine on HMGCoA

reductase has not been studied.
Familial dysbetalipoproteinemia (familial Type III
lipoproteinemia) is characterized by increased levels
of very low density and intermediate density
lipoproteins (Havel et al., 1980).

Clearance of

chylomicrons and very low density lipoproteins is
impaired and leads to an increase in cholesterol-rich
remnant particles (Hazzard and Bierman, 1976; Chait et
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al., 1978; Havel, 1982).

Cholesterol-fed rabbits,

including the cholesterol treated rabbits in this
study, exhibit similar increases in very low density
and intermediate density lipoproteins (Shore et al.,
1974; Kushwaha and Hazzard, 1978).

Ross and Zilversmit

(1977) found that increased chylomicron remnants
constituted the majority of these lipoproteins.
While cholesterol-fed rabbits exhibit a lipoprotein
profile similar to that in Type III
hypercholesterolemia, the mechanism of increased
cholesterol levels differ.

Hypercholesterolemic

rabbits result not from alterations in apoprotein E,
but from saturation of hepatic lipoprotein receptors
and a simultaneous decrease in the number of hepatic
lipoprotein receptors (Kita et al., 1981; Kovanen et
al., 1981).

The mechanism of the hypocholesterolemic

observed in rabbits may not be the same as that
observed in humans.
Humans with familial dysbetalipoproteinemia
(familial Type III hyperlipidemia) possess a variation
in apolipoprotein E which is needed for recognition of
remnant particles by hepatic lipoprotein receptors.
The alteration in apoprotein E reduces recognition,
binding and uptake of very low density lipoprotein
remnants by hepatic cells and results in greatly
increased serum cholesterol levels (Havel, 1982).
The varient apoprotein E in Type III
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hyperlipoproteinemia, i.e apolipoprotein E2, results from a
cysteine for arginine substitution at residues 112 and
158 (Weisgraber et al.,

1981).

Another form,

apoprotein E3, has one cysteine for arginine
substitution at residue 112.

These substitutions

result in altered lipoprotein charges and are
associated with decreased in binding to LDL receptors
(Schneider et al., 1981), with apoprotein E2 showing
the most dramatic decrease in binding capacity.
Cysteamine and cystamine have been proposed as
hypocholesterolemic agents for patients with familial
dysbetalipoproteinemia (Fisher and Gahl, 1982;
Weisgraber et al., 1982; Hui et al., 1984; Innerarity
et al., 1984; Gahl et al., 1985a).

Cysteamine and

cystamine alter the charge on apolipoprotein E in vitro
by forming a mixed disulfide with cysteine and
converting it to a lysine analogue (Fisher and Gahl,
1982; Weisgraber et al., 1982; Rall et al., 1983).
Cysteamine treatment increases LDL receptor binding
activity but does not return binding capacity to normal
levels.

Innerarity et al. (1984) confirm the increased

receptor binding of apoprotein E2 with cysteamine
treatment but note that the increased activity is
retained following reversal of the charge modification.
Positive charge may not be the only cause of improved
binding activity.
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Alteration of defective apolipoproteins with
cysteamine in serum from Type III hyperlipidemic
patients suggests a possible mechanism for cysteamine's
hypolipidemic effect in rabbits, but, to date, the
effect of cysteamine treatment in patients with Type
III hyperlipoproteinemia or with other types of lipid
disorders has not been studied,
Another possible mechanism for cystamine's
hypocholesterolemic action is through alterations in
hormone regulation.

Cystamine treatment in rats is

associated with alterations of some hormones.
Cysteamine depletes tissues of somatostatin (Seiler et
al., 1983; Szabo and Reichlin, 1985) and lowers the
noradrenaline of the hypothalmus in rats (Vecsei et
al., 1985).

Cystinotic children receiving cysteamine

show altered prolactin response (Millard et al., 1982).
Conclusions
Pantethine and cystamine appear equally effective
at lowering serum cholesterol levels in
hypercholesterolemic rabbits.

Current reseach on the

use of pantethine has not considered its metabolites as
possible hypocholesterolemic agents.

In view of

results presented in this study, previous research
designs should be repeated on animals and
hyperlipidemic patients using cystamine as one test
agent.

Of particular interest would be studies
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involving the effect of pantethine and cystamine
treatment in patients with Type III
hyperlipoproteinemia.

The possibility of a dose-

related response for cystamine also needs further
testing.
Possible cholesterol-lowering mechanisms for
cysteamine include inhibition of HMGCoA, alterations in
apoprotein levels or binding capacity, or changes
occurring through endocrine regulation.
Cysteamine's major physiological actions result
from its ready ability to form mixed disulfides with
many compounds.

Future research into cystamine's

hypocholesterolemic action might focus on the formation
of disulfides as a possible mechanism.
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Appendix

.l..:..

Serum Cholesterol Levels of

Individual Rabbits by Group-Experiment 1.

Cholesterol Only Group
Week

Rabbit

6

0
1
2
3
4
5

87
463
813
827
1104
1214

7

57
298
691
811
980
1069

12

Average
x
SD

72
388
680
807
966
1079

70
383
728
815
1017
1121

18
83
74
11
76
81

Pantethine Group
Week

Rabbit

3

0
1
2
3
4
5

131
372
735
663
1038
1155

4

5

63
174
516
634
746
861

47
165
447
530
730
734

11

60
283
521
501
598
706

Average
SD

x

75
249
555
582
778
864

18
98
125
79
186
205

Pantothenic Acid Group
Week

Rabbit

2

0
1
2
3
4
5

66
351
749
856
1270
1379

10

8

58
228
629
763
1124
1328

69
368
835
824
1127
1106

C~stamine

Week

3

4
5

90
221
561
685
1054
1241

Average

x

SD

71
292
694
782
1144
1264

14
78
122
75
91
120

Group

Rabbit

9

0
1
2

15

48
235
456
578
699
667

13

14

62
186
529
613
1028
1077

80
479
727
695
672
673

Average
x
SD

63
300
571
630
800
806

16
157
140
62
198
235
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Appendix

~

Serum Cholesterol Levels of

Individual Rabbits by Treatement
Groups--Experiment

~

Cholesterol Only Group
Week

Rabbit

1

0
1
2
3
4
5
6
7

5

45
190
260
420
430
900
1265
1120

6

65
305
720
990
1030
1540
1865
1560

13

75
40
340
660
660
920
1120
1080

Average
x
SD

50
480
860
1020
520
1260
1320
1345

60
254
545
773
660
1155
1393
1276

12
186
290
286
264
305
326
222

Cl'.:stamine Group
Week

0
1
2
3
4
5
6
7

Rabbit

2

7

60
275
340
510
440
760
960
960

70
235
380
600
480
1025
1095
1070

9

50
265
460
600
590
1190
1270
1375

14

60
220
460
540
930
880
985
1065

Average
x
SD

60
249
410
563
610
964
1078
1118

8
26
60
45
223
186
141
179

Cystine Group
Rabbit

Week

0
1
2
3
4
5
6
7

4

8

60
400
900
1080
910
1560
1480
1680

55
130
360
960
960
1520
1560
1400

11

15

60
265
460
720
720
1240
1375
1295

65
90
280
400
400
710
800
800

Average
SD

x

60
221
496
742
750
1258
1304
1294

4
141
280
326
254
392
344
367

2 2 Hrctroxrethrl Group
Week

Rabbit
3

0
1
2
3
4
5
6

7

50
35
200
480
630
950
1265
1360

10

12

16

60
420
550
390
530
820
985
1375

50
400
880
1150
920
1360
1465
1775

150
375
500
600
600
1080
1240
1680

Average
x
SD
78
308
538
655
670
1053
1239
1548

49
183
284
341
172
231
197
211

